CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hepion Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hepion Pharmaceuticals Inc
399 Thornall St
Phone: (732) 902-4000p:732 902-4000 EDISON, NJ  08837-2236  United States Ticker: HEPAHEPA
Business Summary
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on artificial intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. Its primary asset, Rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models. Its drug candidate is intended to target multiple molecular pathways across the full spectrum of liver disease progression, from the triggering events that initiate disease to the pathological events that directly impair liver function and integrity. Its AI-POWR platform provides integrative, multi-variate, systems-biology bioinformatic and big-data analysis of proprietary pre-clinical and clinical data with publicly available multi-omic databases.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Interim Chief Executive Officer, Interim Chief Financial Officer John P.Brancaccio 76 8/6/2024 5/15/2013
Independent Director Timothy M.Block 68 11/26/2013 11/26/2013
Independent Director KaoutharLbiati 45 6/27/2022 6/27/2022
Independent Director MichaelPurcell 67 3/5/2024 3/5/2024

Business Names
Business Name
Ciclofilin Pharmaceuticals, Inc.
ContraVir Research, Inc.
CTRV
HEPA
Hepion Research Corp.

General Information
Number of Employees: 22 (As of 12/31/2023)
Outstanding Shares: 1,085,014 (As of 3/18/2025)
Shareholders: 344
Stock Exchange: NASD
Federal Tax Id: 462783806
Fax Number: (732) 902-4100


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 28, 2025